Shanghai Henlius Biotech (SEHK:2696) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

2696 주식 개요

는 종양학, 자가 면역 질환 및 안과 질환에 중점을 둔 생물학적 의약품의 연구 및 개발에 종사하고 있습니다.

2696 기본 분석
눈송이 점수
가치 평가	4/6
미래 성장	4/6
과거 실적	3/6
재무 상태	3/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 71.3% 에서 거래

수익은 매년 15.77% 증가할 것으로 예상됩니다.

올해부터 흑자전환

위험 분석

부채비율이 높네요

Shanghai Henlius Biotech, Inc. 경쟁사

Shanghai Haohai Biological Technology

SEHK:6826

HK$14.1b

3SBio

SEHK:1530

HK$15.2b

Akeso

SEHK:9926

HK$32.7b

CK Life Sciences Int'l. (Holdings)

SEHK:775

HK$3.1b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Shanghai Henlius Biotech
과거 주가
현재 주가	HK$22.85
52주 최고치	HK$23.05
52주 최저치	HK$9.60
베타	0.85
11개월 변경	21.28%
3개월 변경 사항	67.77%
1년 변경 사항	105.86%
33년 변화	-40.26%
5년 변화	n/a
IPO 이후 변화	-53.79%

최근 뉴스 및 업데이트

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

May 25

Recent updates

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

May 25

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 25

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Mar 10

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Dec 31

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Nov 25

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 18

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Aug 03

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

May 31

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Apr 06

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 22

주주 수익률

	2696	HK Biotechs	HK 마켓
7D	21.3%	-0.7%	-1.0%
1Y	105.9%	-34.6%	0.7%

수익률 대 산업: 2696 지난 1년 동안 -34.3 %를 반환한 Hong Kong Biotechs 산업을 초과했습니다.

수익률 대 시장: 2696 지난 1년 동안 2.1 %를 반환한 Hong Kong 시장을 초과했습니다.

가격 변동성

Is 2696's price volatile compared to industry and market?
2696 volatility
2696 Average Weekly Movement	8.0%
Biotechs Industry Average Movement	8.9%
Market Average Movement	7.0%
10% most volatile stocks in HK Market	14.9%
10% least volatile stocks in HK Market	3.7%

안정적인 주가: 2696 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: 2696 의 주간 변동성( 4% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2010	3,637	Jason Zhu	www.henlius.com

는 종양학, 자가 면역 질환 및 안과 질환에 중점을 둔 생물학적 의약품의 연구 및 개발에 종사하고 있습니다. 비호지킨 림프종, 만성 림프구성 백혈병, 류마티스 관절염 치료용 리툭시맙 주사제인 한리캉과 유방암 및 전이성 유방암과 위암 치료용 트라스투주맙 주사제인 한쿠유를 제공합니다; 류마티스 관절염, 강직성 척추염, 판상 건선, 포도막염 치료를 위한 아달리무맙 주사제인 한다유안, 전이성 대장암(mCRC) 및 재발성 비소세포 폐암 치료를 위한 베바시주맙 주사제인 한베이타이, 미세 위성 불안정성 고형 종양을 위한 세르플리맙 주사제인 한시주앙 등이 있습니다. 또한 회사는 편평세포암, 위암, 소세포폐암, 간세포암, 전이성 대장암, 고형 종양, SCCHN, sqNSCLC, 간세포암, 식도 편평세포암 치료를 위한 세르플리맙과 습성 연령 관련 황반변성을 위한 항-VEGF 단클론 항체 주사제인 HLX04-O를 개발 중입니다; 유방암 및 전이성 위암 치료제 HLX22, 특발성 폐섬유증 치료제 HLX6018, 고형암 치료제 HLX07, HLX22, HLX208, HLX60, HLX42, HLX43, HLX53, HLX51, 유방암 치료제 HLX11, mCRC 및 SCCHN 치료제 세툭시맙 주사제인 HLX05, 골다공증 치료제 HLX14 등이 있습니다.

Shanghai Henlius Biotech, Inc. 기본 사항 요약

Shanghai Henlius Biotech 의 수익과 매출은 시가총액과 어떻게 비교하나요?
2696 기본 통계
시가총액	HK$12.42b
수익(TTM)	HK$586.71m
수익(TTM)	HK$5.80b

21.2x

P/E 비율

2.1x

P/S 비율

2696 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
2696 손익 계산서(TTM)
수익	CN¥5.39b
수익 비용	CN¥1.48b
총 이익	CN¥3.92b
기타 비용	CN¥3.37b
수익	CN¥546.02m

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	1.00
총 마진	72.64%
순이익 마진	10.12%
부채/자본 비율	174.2%

2696 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

2696 주식 개요

보상

위험 분석

Shanghai Henlius Biotech, Inc. 경쟁사

SEHK:6826

HK$14.1b

SEHK:1530

HK$15.2b

SEHK:9926

HK$32.7b

SEHK:775

HK$3.1b

가격 내역 및 성능

최근 뉴스 및 업데이트

Shanghai Henlius Biotech, Inc. Announces Completion of Phase 1 Clinical Study of a Biosimilar of Daratumumab HLX15 (Recombinant Anti-CD38 Human Monoclonal Antibody

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) agreed to acquire 78.3% stake in Shanghai Henlius Biotech, Inc. (SEHK:2696) from a group of shareholders for CNY 4.3 billion.

Investor sentiment improves as stock rises 19%

Less than half of directors are independent

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

Recent updates

Shanghai Henlius Biotech, Inc. Announces Completion of Phase 1 Clinical Study of a Biosimilar of Daratumumab HLX15 (Recombinant Anti-CD38 Human Monoclonal Antibody

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) agreed to acquire 78.3% stake in Shanghai Henlius Biotech, Inc. (SEHK:2696) from a group of shareholders for CNY 4.3 billion.

Investor sentiment improves as stock rises 19%

Less than half of directors are independent

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

National Medical Products Administration Approves Shanghai Henlius Biotech, Inc.'S the Supplemental Applications of Handayuan (Adalimumab Injection) for the New Indications

Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration (FDA)

Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China

Shanghai Henlius Biotech, Inc., Annual General Meeting, May 20, 2024

Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration

New major risk - Financial position

Shanghai Henlius Biotech, Inc. Announces Dosing of First Subject in A Phase 1 Clinical Studyin Healthy Chinese Male Subjects of Ipilimumab Biosimilarhlx13 (Recombinant Anti-Ctla-4 Fully Human Monoclonalantibody Injection)

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Shanghai Henlius Biotech, Inc. Receives Approval from United States Food and Drug Administration for Application for Phase 1 Clinical Trial of HLX42 for Injection (Antibody-Drug Conjugate Targeting EGFR with Novel DNA Topoisomerase I Inhibitor)

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13

New minor risk - Financial position

Shanghai Henlius Biotech, Inc. to Report Nine Months, 2023 Results on Nov 15, 2023

Shanghai Henlius Biotech, Inc. Announces Shenzhen Nansiuzhuiang in Combination with Chemotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Shanghai Henlius Biotech, Inc. Announces NMPA Approvals of Two ADC Candidates for IND

Shanghai Henlius Biotech, Inc. Announces the First Patient in Europe Has Been Dosed in the International Multi-Centre Phase 3 Clinical Trial

Shanghai Henlius Biotech, Inc. Appoints Wei Huang as President

Shanghai Henlius Biotech, Inc. Announces the New Drug Application (Nda) for New Indication of Hansizhuang (Serplulimab Injection) an Innovative Anti-PD-1 Monoclonal Antibody

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. Announces Executive Appointments

First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.47 loss in 1H 2022)

Shanghai Henlius Biotech, Inc. to Report Q2, 2023 Results on Aug 25, 2023

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces Resignation of Zihou Yan as Non-Executive Director, Member of the Strategy Committee and Environmental, Social and Governance Committee

Consensus EPS estimates fall by 31%

Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Financial Guidance for the Six Months Ended 30 June 2023

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Phase 2 Clinical Trial of HLX26

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

Shanghai Henlius Biotech, Inc. Announces Application for Phase 2 Clinical Trial of Hlx26

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Consensus revenue estimates increase by 13%

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces United States Food and Drug Administration Accepts the Biologic License Application for HLX02

Shanghai Henlius Biotech, Inc. Announces the First Patient in USA Has Been Dosed in Aninternational Multicentre Phase 3 Clinical Study Ofrecombinant Anti-Vegf Humanised Monoclonalantibody Ophthalmic Injection Hlx04-Ofor the Treatment of Wet Age-Related Maculardegeneration (Wamd)

Shanghai Henlius Biotech, Inc. Announces the Phase 1b/2 Clinical Trial of Hlx07

Shanghai Henlius Biotech, Inc. Announces Dosage of First Subject in Phase 1 Clinical Study of HLX15 (Recombinant Anti-CD38 Humanmonoclonal Antibody Injection) in Healthy Chinese Male Subjects

Shanghai Henlius Biotech, Inc. Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC

Shanghai Henlius Biotech Announces the First Patient Dosage in the United States of America in an International Multi-Centre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection)